Back to Search
PERRY RICHARDSON, MD
MD
Clinical Neurophysiology Physician
NPI: 1427022086IndividualAccepts Medicare
Specialties, Licenses & Credentials
Neurology Physician
Psychiatry & Neurology — Neurology
Code: 2084N0400X
21085753(DC)
Clinical Neurophysiology PhysicianPrimary
Psychiatry & Neurology — Clinical Neurophysiology
Code: 2084N0600X
D21085(DC)
CMS Specialties
PrimaryNEUROLOGY
Education
GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Class of 1984
Research & Publications (20)
The effects of flexible bronchoscopy on mechanical ventilation in a pediatric lung model.
PMID 18812449·Chest·2009
8-other
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
PMID 19494840·Leukemia·2009
6-review
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
PMID 19584292·Cancer Res·2009
7-preclinical
Therapeutic intent of proton pump inhibitor prescription among elderly nonsteroidal anti-inflammatory drug users.
PMID 19573167·Aliment Pharmacol Ther·2009
8-other
The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.
PMID 19568229·Am J Gastroenterol·2009
8-other
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
PMID 19561323·Blood·2009
8-other
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
PMID 19554029·Leukemia·2009
6-review
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
PMID 19545290·Br J Haematol·2009
8-other
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
PMID 19528374·J Clin Oncol·2009
8-other
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
PMID 19509164·Clin Cancer Res·2009
7-preclinical
Maximizing the clinical benefit of novel therapies in multiple myeloma.
PMID 19476274·Oncology (Williston Park)·2009
6-review
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
PMID 19471019·Blood·2009
3-trial
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
PMID 19452315·Leuk Lymphoma·2009
6-review
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
PMID 19436050·Blood·2009
7-preclinical
Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.
PMID 19644143·Haematologica·2009
8-other
Targeting a dominant negative rho kinase to neurons promotes axonal outgrowth and partial functional recovery after rat rubrospinal tract lesion.
PMID 19623163·Mol Ther·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2150 PENNSYLVANIA AVE., NW
WASHINGTON DC, DC 20037 - Phone
- (202) 741-2700
Quick Facts
- NPI
- 1427022086
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile